Enclomiphene

Gonadorelin supplies the GnRH pulse directly while enclomiphene removes the estrogen feedback that is blunting the pituitary's response to it, which addresses two different failure points in a stalled restart.

Enclomiphene drives pituitary LH and FSH without zuclomiphene's estrogenic baggage while HCG holds intratesticular testosterone up from the testicular side, which is the cleaner version of the classic restart pair.

Enclomiphene removes the estrogen brake on the hypothalamus and pituitary while kisspeptin supplies positive drive to the GnRH neurons themselves, which are two different levers on the same stalled axis.

Losing significant body fat raises endogenous testosterone by reducing aromatase load, and enclomiphene drives the pituitary side of the same axis, so the two work on secondary hypogonadism from opposite ends.

Raloxifene covers breast tissue during the estradiol swing of a restart without competing for the pituitary drive, because unlike tamoxifen it barely stimulates LH and FSH.

Enclomiphene carries the gonadotropin drive without zuclomiphene's estrogenic accumulation while tamoxifen covers the breast tissue that the estradiol rise of a restart threatens.